Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.92 AUD 3.14% Market Closed
Market Cap: 418.6m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note

Relative Value

The Relative Value of one MYX stock under the Base Case scenario is 10.8 AUD. Compared to the current market price of 4.92 AUD, Mayne Pharma Group Ltd is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MYX Relative Value
Base Case
10.8 AUD
Undervaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
53
vs Industry
63
Median 3Y
1.6
Median 5Y
1
Industry
2.5
Forward
0.9
vs History
vs Industry
42
Median 3Y
-1.9
Median 5Y
-4.8
Industry
21.9
Forward
-21
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-56
Industry
16.5
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-7.1
Industry
23.6
vs History
17
vs Industry
69
Median 3Y
0.7
Median 5Y
0.6
Industry
2.1
vs History
49
vs Industry
73
Median 3Y
1.6
Median 5Y
0.6
Industry
2.6
Forward
0.6
vs History
50
vs Industry
78
Median 3Y
2.5
Median 5Y
1.1
Industry
5.2
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-37.2
Industry
13.3
Forward
4.7
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-37.2
Industry
16.6
Forward
-12.7
vs History
vs Industry
Median 3Y
-15.9
Median 5Y
-51.8
Industry
15.6
vs History
vs Industry
Median 3Y
-9
Median 5Y
-96.6
Industry
19.1
vs History
65
vs Industry
81
Median 3Y
0.3
Median 5Y
0.4
Industry
1.9

Multiples Across Competitors

MYX Competitors Multiples
Mayne Pharma Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Mayne Pharma Group Ltd
ASX:MYX
399.7m AUD 1 -2.3 -1.8 -1.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
744.2B USD 18.2 88.9 47.8 53.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.2 34.9 24.2 27.7
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 4.3 25.5 12.3 16
US
Merck & Co Inc
NYSE:MRK
258.4B USD 4.1 21.3 10.7 12.9
CH
Roche Holding AG
SIX:ROG
200.6B CHF 3.4 17.4 9.8 11.7
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.2 31.8 169.4 253.9
CH
Novartis AG
SIX:NOVN
180.7B CHF 4.1 11.6 10 14
US
Pfizer Inc
NYSE:PFE
146.9B USD 2.4 34.3 10.3 15.6
P/E Multiple
Earnings Growth
AU
Mayne Pharma Group Ltd
ASX:MYX
Average P/E: 33.2
Negative Multiple: -2.3
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
88.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
34.9
86%
US
Johnson & Johnson
NYSE:JNJ
25.5
-22%
US
Merck & Co Inc
NYSE:MRK
21.3
7 321%
CH
Roche Holding AG
SIX:ROG
17.4
32%
UK
AstraZeneca PLC
LSE:AZN
31.8
177%
CH
Novartis AG
SIX:NOVN
11.6
21%
US
Pfizer Inc
NYSE:PFE
34.3
733%
EV/EBITDA Multiple
EBITDA Growth
AU
Mayne Pharma Group Ltd
ASX:MYX
Average EV/EBITDA: 460.1
Negative Multiple: -1.8
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
195%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
DK
Novo Nordisk A/S
CSE:NOVO B
24.2
84%
US
Johnson & Johnson
NYSE:JNJ
12.3
14%
US
Merck & Co Inc
NYSE:MRK
10.7
331%
CH
Roche Holding AG
SIX:ROG
9.8
23%
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
CH
Novartis AG
SIX:NOVN
10
8%
US
Pfizer Inc
NYSE:PFE
10.3
31%

See Also

Discover More
Back to Top